Education
About Us
Working with TipRanks
Follow Us
Argenx Se (ARGX)
NASDAQ:ARGX
ARGX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$352.77 - $678.21
Previous CloseN/A
Volume151.62K
Average Volume (3M)397.06K
Market Cap
$39.69B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)47.3
Beta0.51
Next Earnings
Jul 31, 2025Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.58
Shares Outstanding61,059,563
10 Day Avg. Volume261,297
30 Day Avg. Volume397,065
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$752.66Price Target Upside32.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceVyvgart posted global sales of $790M, beating consensus, showing robust profitability.
Market ExpansionThe pre-filled syringe is likely to capture a meaningful part of the market by allowing at-home administration, potentially drawing share from existing treatments and expanding the market.
Product DevelopmentThe pre-filled syringe formulation of Vyvgart Hytrulo has been approved in the U.S., addressing investor concerns about timing and process related to FDA turmoil.
Bears Say
Investor ExpectationsExpectations were higher than consensus, and management did not provide patient numbers on the call.
Investor SentimentDespite strong sales, argenx stock is trading down by about 10% premarket, likely due to high investor expectations around the CIDP indication launch.
Revenue ImpactSeasonality and reimbursement shift toward Part D contributed to revenue weakness.
---
Ownership Overview
―
Insiders
14.77% Mutual Funds
0.24% Other Institutional Investors
83.44% Public Companies and
Individual Investors
ARGX FAQ
What was Argenx Se’s price range in the past 12 months?
Argenx Se lowest stock price was $352.77 and its highest was $678.21 in the past 12 months.
What is Argenx Se’s market cap?
Argenx Se’s market cap is $39.69B.
When is Argenx Se’s upcoming earnings report date?
Argenx Se’s upcoming earnings report date is Jul 31, 2025 which is in 83 days.
How were Argenx Se’s earnings last quarter?
Argenx Se released its earnings results on May 08, 2025. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.421 by $0.159.
Is Argenx Se overvalued?
According to Wall Street analysts Argenx Se’s price is currently Undervalued.
Does Argenx Se pay dividends?
Argenx Se does not currently pay dividends.
What is Argenx Se’s EPS estimate?
Argenx Se’s EPS estimate is 3.
How many shares outstanding does Argenx Se have?
Argenx Se has 61,059,563 shares outstanding.
What happened to Argenx Se’s price movement after its last earnings report?
Argenx Se reported an EPS of $2.58 in its last earnings report, beating expectations of $2.421. Following the earnings report the stock price went down -8.638%.
Which hedge fund is a major shareholder of Argenx Se?
Currently, no hedge funds are holding shares in ARGX
---
Argenx Se Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$752.66 (32.25% Upside)
$752.66 (32.25% Upside)
Blogger Sentiment
Bullish
ARGX Sentiment 83%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 53.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 8.4%
Last 30 Days ▲ 8.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.20%
12-Months-Change
Fundamentals
Return on Equity
17.33%
Trailing 12-Months
Asset Growth
36.55%
Trailing 12-Months
Company Description
Argenx Se
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
---
ARGX Company Deck
---
ARGX Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant commercial success with record-breaking revenue growth and successful product launches. The company is in a strong financial position and advancing its pipeline with promising data presentations. However, there were challenges related to seasonality, gross-to-net impacts, and unique market dynamics in CIDP that affected growth. Overall, the sentiment is positive due to the strong growth and strategic advancements outweighing the lowlights.Read More>---
ARGX Stock 12 Month Forecast
Average Price Target
$752.66
▲(32.25% Upside)
Technical Analysis
---